NASDAQ:FBLG FibroBiologics Q3 2025 Earnings Report $0.77 -0.03 (-3.73%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$0.79 +0.02 (+2.57%) As of 06/18/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast FibroBiologics EPS ResultsActual EPS-$2.60Consensus EPS -$2.00Beat/MissMissed by -$0.60One Year Ago EPSN/AFibroBiologics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AFibroBiologics Announcement DetailsQuarterQ3 2025Date10/31/2025TimeAfter Market ClosesConference Call DateFriday, October 31, 2025Conference Call Time4:00PM ETUpcoming EarningsFibroBiologics' Q2 2026 earnings is estimated for Thursday, July 30, 2026, based on past reporting schedules, with a conference call scheduled at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsEarnings Release(8-K)Quarterly Report(10-Q) FibroBiologics Earnings HeadlinesFibroBiologics Advances Patient Dosing for Phase 1/2 Clinical Trial of CYWC628 for the Treatment of Diabetic Foot UlcersJune 16 at 8:30 AM | globenewswire.comFibroBiologics (NASDAQ:FBLG) Rating Increased to Sell at Wall Street ZenJune 13, 2026 | americanbankingnews.comWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillion in stored capital will be looking for a home when it does. But the real opportunity isn't the IPO itself. Jovine has identified a small-cap supplier trading near $4 that sits directly in the path of xAI's Colossus infrastructure buildout - and a specific trigger in the S-1 could reprice it overnight. | Behind the Markets (Ad)FBLG: Phase 1/2 trial of CYWC628 underwayJune 4, 2026 | msn.comEXCLUSIVE: FibroBiologics Doses First Patients In Diabetic Foot Ulcers Clinical TrialJune 3, 2026 | benzinga.comFibroBiologics Announces First Patients Dosed in Phase 1/2 Clinical Trial Evaluating CYWC628 for the Treatment of Diabetic Foot UlcersJune 3, 2026 | globenewswire.comSee More FibroBiologics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like FibroBiologics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on FibroBiologics and other key companies, straight to your email. Email Address About FibroBiologicsFibroBiologics (NASDAQ:FBLG), Inc. operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics, Inc. was incorporated in 2021 and is based in Houston, Texas.View FibroBiologics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Credo Technologies Accelerates AI—Its Stock Price Will FollowCarMax In Reverse? Why You Should Buy Now Before the Big Catalysts EmergeJabil Just Gave Investors a Stronger Reason to Buy the DipCan Trupanion Turn Pet Insurance Loyalty Into Real Earnings?Okta’s AI Moment May Be Bigger Than Investors RealizeDave & Buster’s Q1 Miss Raises the Stakes for Its Turnaround PlanMicrosoft’s Xbox Problem Is Bigger Than a Console War Upcoming Earnings FedEx (6/23/2026)Micron Technology (6/24/2026)NIKE (6/30/2026)PepsiCo (7/9/2026)Delta Air Lines (7/9/2026)Fastenal (7/13/2026)Bank of America (7/14/2026)The Goldman Sachs Group (7/14/2026)JPMorgan Chase & Co. (7/14/2026)Wells Fargo & Company (7/14/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
